G
Gabriel Etienne
Researcher at French Institute of Health and Medical Research
Publications - 179
Citations - 10857
Gabriel Etienne is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 38, co-authored 163 publications receiving 9386 citations. Previous affiliations of Gabriel Etienne include University of Bordeaux & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio,Dong-Wook Kim,Surapol Issaragrisil,Gabriel Etienne,Clarisse Lobo,Ricardo Pasquini,Richard E. Clark,Andreas Hochhaus,Timothy P. Hughes,Neil Gallagher,Albert Hoenekopp,Mei Dong,Ariful Haque,Richard A. Larson,Hagop M. Kantarjian +14 more
TL;DR: Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive CML, and no patient with progression to the accelerated phase or blast crisis had a major molecular response.
Journal ArticleDOI
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon,Delphine Rea,Joelle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Etienne,Josy Reiffers,Philippe Rousselot +12 more
TL;DR: Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors.
Journal ArticleDOI
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Andreas Hochhaus,Giuseppe Saglio,Timothy P. Hughes,Richard A. Larson,Dong-Kee Kim,Surapol Issaragrisil,P. le Coutre,Gabriel Etienne,Pedro Enrique Dorlhiac-Llacer,Richard E. Clark,Ian W. Flinn,Hirohisa Nakamae,Breanne Donohue,Weiping Deng,Darshan Dalal,Hans D. Menssen,Hagop M. Kantarjian +16 more
TL;DR: Long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP, and few deaths in any arm were associated with CVEs, infections or pulmonary diseases.
Journal ArticleDOI
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Picard Stephane,Karine Titier,Gabriel Etienne,Emmanuelle Teilhet,Dominique Ducint,M.-A. Bernard,Régis Lassalle,Gerald Marit,Josy Reiffers,Bernard Bégaud,Nicholas Moore,Mathieu Molimard,Francois-Xavier Mahon +12 more
TL;DR: Monitoring of imatinib plasma levels could be very useful for the management of patients with CML or should at least be checked in the case of treatment failure or suboptimal response.
Journal ArticleDOI
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Richard A. Larson,Andreas Hochhaus,Timothy P. Hughes,Richard E. Clark,Gabriel Etienne,Dong-Kee Kim,Ian W. Flinn,Mineo Kurokawa,Beatriz Moiraghi,Richard Yu,Rick E. Blakesley,Neil Gallagher,Giuseppe Saglio,Hagop M. Kantarjian +13 more
TL;DR: Nilotinib continues to demonstrate superior efficacy in all key response and outcome parameters compared with imatinib for the treatment of patients with newly diagnosed CML-CP and was associated with a significantly lower probability of progression to accelerated phase/blast crisis vs imatinIB.